Published in Drug Week, April 6th, 2001
"There is a growing scientific basis for investigating Trisenox in a variety of blood-related cancers and strong interest among leading hematologists to study Trisenox in diseases such as leukemia, MDS, and multiple myeloma," stated James A. Bianco, MD, Cell Therapeutics. "Combined with the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.